IMMP

Immutep Limited is a biotechnology company focused on developing novel immunotherapy products for cancer and autoimmune diseases. The company's lead technology platform is based on LAG-3, an immune control mechanism that plays a role in regulating T cell function. Immutep's pipeline includes both agonist and antagonist LAG-3 products designed to either stimulate or suppress immune responses depending on the therapeutic application. The company has partnered with major pharmaceutical companies to advance its programs. Immutep's approach targets fundamental mechanisms of immune regulation with potential applications across multiple disease areas.